← Back to Screener
AEON Biopharma, Inc. (AEON)
Price$1.07
Favorite Metrics
Price vs S&P 500 (26W)-18.48%
Price vs S&P 500 (4W)-14.17%
Market Capitalization$25.81M
P/E Ratio (Annual)0.54x
All Metrics
Book Value / Share (Quarterly)$1.09
P/TBV (Annual)0.74x
Cash Flow / Share (Quarterly)$-1.43
Price vs S&P 500 (YTD)-11.41%
EPS (TTM)$-1.59
10-Day Avg Trading Volume0.19M
EPS Excl Extra (TTM)$-1.59
EPS (Annual)$-3.95
ROI (Annual)2.31%
Cash / Share (Quarterly)$0.25
P/E Normalized (Annual)0.54x
ROA (Last FY)-705.43%
EBITD / Share (TTM)$-0.32
Cash Flow / Share (Annual)$-1.43
P/B Ratio (Quarterly)4.90x
Net Income / Employee (Annual)$-7
Net Interest Coverage (TTM)-0.09x
ROA (TTM)-394.64%
EV / EBITDA (TTM)33.87x
EPS Incl Extra (Annual)$-3.95
Current Ratio (Annual)0.49x
Quick Ratio (Quarterly)0.44x
3-Month Avg Trading Volume0.16M
52-Week Price Return155.06%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$1.09
52-Week High$1.45
EPS Excl Extra (Annual)$-3.95
26-Week Price Return-9.73%
Quick Ratio (Annual)0.44x
13-Week Price Return-7.90%
Total Debt / Equity (Annual)0.06x
Current Ratio (Quarterly)0.49x
Enterprise Value$57.403
Revenue / Employee (Annual)$0
Cash / Share (Annual)$0.25
3-Month Return Std Dev91.07%
Net Income / Employee (TTM)$-7
ROE (Last FY)2.41%
Net Interest Coverage (Annual)-0.09x
EPS Basic Excl Extra (Annual)$-3.95
Total Debt / Equity (Quarterly)10.28x
EPS Incl Extra (TTM)$-1.59
ROI (TTM)-1.80%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$7.80
Price vs S&P 500 (52W)119.97%
Year-to-Date Return-7.27%
5-Day Price Return18.69%
EPS Normalized (Annual)$-3.95
ROA (5Y Avg)-1267.96%
Month-to-Date Return3.55%
EBITD / Share (Annual)$-0.32
EPS Basic Excl Extra (TTM)$-1.59
P/TBV (Quarterly)20.47x
P/B Ratio (Annual)0.69x
Book Value / Share (Annual)$7.80
Price vs S&P 500 (13W)-10.77%
Beta0.72x
Revenue / Share (TTM)$0.00
ROE (TTM)-1.74%
52-Week Low$0.38
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.13
4.13
4.13
4.13
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
AEONAEON Biopharma, Inc. | — | — | — | — | $1.07 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
AEON Biopharma is a clinical-stage biopharmaceutical company developing ABP-450 (prabotulinumtoxinA), a proprietary botulinum toxin complex for treating debilitating medical conditions. The company is initially focusing on neuroscience indications where there is significant unmet medical need. ABP-450 represents AEON's lead therapeutic program aimed at patients with conditions that have limited treatment options.